Stay updated on Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial page.

Latest updates to the Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial page
- Check7 days agoChange DetectedThe page no longer displays the disease name 'Multiple myeloma' or its related topics. This reduces disease context and discoverability for the trial.SummaryDifference0.1%

- Check14 days agoChange DetectedMinor metadata updates: 'Multiple myeloma' added as a related topic and 'MedlinePlus Genetics' linked; page revision updated to v3.4.2, with the old funding notice and v3.4.1 removal. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a government funding and NIH Clinical Center status notice and updated the site revision to v3.4.1; removed reference to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check29 days agoChange DetectedAdded a glossary display, added Last Update Submitted that Met QC Criteria, and updated footer notes to No FEAR Act Data with revision to v3.4.0. Removed the term 'Multiple Myeloma' and related topics such as MedlinePlus Genetics, and adjusted capitalization for No FEAR Act data and Revision: v3.3.4.SummaryDifference0.2%

- Check43 days agoChange DetectedRevision: v3.3.4 is shown on the page, and the disease term 'Multiple myeloma' and related topics such as 'MedlinePlus Genetics' were removed from the related topics section. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a Locations section listing study sites across multiple states and updated the page revision to v3.3.3.SummaryDifference0.7%

Stay in the know with updates to Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial page.